• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于呼吸道给药的可吸入聚乙二醇化磷脂纳米载体和聚乙二醇化治疗药物,以雾化胶体分散体和干粉吸入器形式呈现

Inhalable PEGylated Phospholipid Nanocarriers and PEGylated Therapeutics for Respiratory Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers.

作者信息

Muralidharan Priya, Mallory Evan, Malapit Monica, Hayes Don, Mansour Heidi M

机构信息

Skaggs Pharmaceutical Sciences Center, College of Pharmacy, the University of Arizona, 1703 E. Mabel St, Tucson, AZ 85721-0202, USA.

Lung and Heart-Lung Transplant Programs, Departments of Pediatrics and Internal Medicine, the Ohio State University College of Medicine, Columbus, OH 43205, USA.

出版信息

Pharmaceutics. 2014 Jun 20;6(2):333-53. doi: 10.3390/pharmaceutics6020333.

DOI:10.3390/pharmaceutics6020333
PMID:24955820
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4085602/
Abstract

Nanomedicine is making groundbreaking achievements in drug delivery. The versatility of nanoparticles has given rise to its use in respiratory delivery that includes inhalation aerosol delivery by the nasal route and the pulmonary route. Due to the unique features of the respiratory route, research in exploring the respiratory route for delivery of poorly absorbed and systemically unstable drugs has been increasing. The respiratory route has been successfully used for the delivery of macromolecules like proteins, peptides, and vaccines, and continues to be examined for use with small molecules, DNA, siRNA, and gene therapy. Phospholipid nanocarriers are an attractive drug delivery system for inhalation aerosol delivery in particular. Protecting these phospholipid nanocarriers from pulmonary immune system attack by surface modification by polyethylene glycol (PEG)ylation, enhancing mucopenetration by PEGylation, and sustaining drug release for controlled drug delivery are some of the advantages of PEGylated liposomal and proliposomal inhalation aerosol delivery. This review discusses the advantages of using PEGylated phospholipid nanocarriers and PEGylated therapeutics for respiratory delivery through the nasal and pulmonary routes as inhalation aerosols.

摘要

纳米医学在药物递送方面正取得突破性成就。纳米颗粒的多功能性使其在呼吸道递送中得到应用,包括通过鼻腔途径和肺部途径进行吸入气雾剂递送。由于呼吸道的独特特性,探索将吸收不良和全身不稳定的药物通过呼吸道递送的研究不断增加。呼吸道已成功用于递送蛋白质、肽和疫苗等大分子,并且仍在研究其用于小分子、DNA、siRNA和基因治疗的情况。磷脂纳米载体尤其适用于吸入气雾剂递送,是一种有吸引力的药物递送系统。通过聚乙二醇(PEG)化进行表面修饰,保护这些磷脂纳米载体免受肺部免疫系统攻击,通过PEG化增强黏液穿透能力,以及维持药物释放以实现可控药物递送,这些都是聚乙二醇化脂质体和前体脂质体吸入气雾剂递送的一些优势。本综述讨论了使用聚乙二醇化磷脂纳米载体和聚乙二醇化治疗药物通过鼻腔和肺部途径作为吸入气雾剂进行呼吸道递送的优势。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41a6/4085602/3dd463c71dc9/pharmaceutics-06-00333-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41a6/4085602/c689cc7ad092/pharmaceutics-06-00333-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41a6/4085602/3dd463c71dc9/pharmaceutics-06-00333-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41a6/4085602/c689cc7ad092/pharmaceutics-06-00333-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41a6/4085602/3dd463c71dc9/pharmaceutics-06-00333-g002.jpg

相似文献

1
Inhalable PEGylated Phospholipid Nanocarriers and PEGylated Therapeutics for Respiratory Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers.用于呼吸道给药的可吸入聚乙二醇化磷脂纳米载体和聚乙二醇化治疗药物,以雾化胶体分散体和干粉吸入器形式呈现
Pharmaceutics. 2014 Jun 20;6(2):333-53. doi: 10.3390/pharmaceutics6020333.
2
Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer.先进喷雾干燥化疗 PEG 化磷脂粒子的特性及其在肺癌干粉吸入递药中的气溶胶分散性能。
Eur J Pharm Sci. 2013 Jul 16;49(4):699-711. doi: 10.1016/j.ejps.2013.05.012. Epub 2013 May 23.
3
Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols.设计、物理化学特性分析和优化有机溶液高级喷雾干燥二棕榈酰磷脂酰胆碱(DPPC)和二棕榈酰磷脂酰乙醇胺聚乙二醇(DPPE-PEG)微米和纳米粒子,用于作为干粉吸入剂气溶胶的靶向呼吸纳米医学递药。
Int J Nanomedicine. 2013;8:275-93. doi: 10.2147/IJN.S30724. Epub 2013 Jan 15.
4
Insulin inhalation--Pfizer/Nektar Therapeutics: HMR 4006, inhaled PEG-insulin--Nektar, PEGylated insulin--Nektar.胰岛素吸入剂——辉瑞/耐科斯特治疗公司:HMR 4006,吸入型聚乙二醇化胰岛素——耐科斯特,聚乙二醇化胰岛素——耐科斯特。
Drugs R D. 2004;5(3):166-70. doi: 10.2165/00126839-200405030-00007.
5
Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.万古霉素和克拉霉素多功能控释粒子的先进喷雾干燥设计、理化特性表征和干粉吸入气溶胶的气溶胶分散性能,用于靶向呼吸递药。
Int J Pharm. 2013 Oct 15;455(1-2):374-92. doi: 10.1016/j.ijpharm.2013.06.047. Epub 2013 Jun 29.
6
Inhaled Nanoparticulate Systems: Composition, Manufacture and Aerosol Delivery.吸入式纳米颗粒系统:组成、制造和气溶胶传递。
J Aerosol Med Pulm Drug Deliv. 2024 Aug;37(4):202-218. doi: 10.1089/jamp.2024.29117.mk.
7
Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide.PEG 化 KL4 合成肽干粉制剂经肺部给药实现有效 mRNA 传递
J Control Release. 2019 Nov 28;314:102-115. doi: 10.1016/j.jconrel.2019.10.026. Epub 2019 Oct 16.
8
Dry powder inhalers in COPD, lung inflammation and pulmonary infections.慢性阻塞性肺疾病中的干粉吸入器、肺部炎症和肺部感染。
Expert Opin Drug Deliv. 2015 Jun;12(6):947-62. doi: 10.1517/17425247.2015.977783. Epub 2014 Nov 12.
9
TPP-dendrimer nanocarriers for siRNA delivery to the pulmonary epithelium and their dry powder and metered-dose inhaler formulations.用于将小干扰RNA递送至肺上皮的三苯基膦树枝状大分子纳米载体及其干粉和定量吸入器制剂。
Int J Pharm. 2017 Jul 15;527(1-2):171-183. doi: 10.1016/j.ijpharm.2017.05.046. Epub 2017 May 23.
10
The interaction of dendrimer-doxorubicin conjugates with a model pulmonary epithelium and their cosolvent-free, pseudo-solution formulations in pressurized metered-dose inhalers.树枝状聚合物-阿霉素缀合物与模型肺上皮细胞的相互作用及其在压力定量吸入器中无共溶剂、假溶液制剂。
Eur J Pharm Sci. 2017 Nov 15;109:86-95. doi: 10.1016/j.ejps.2017.07.030. Epub 2017 Jul 31.

引用本文的文献

1
Intranasally administrated fusion-inhibitory lipopeptides block SARS-CoV-2 infection in mice and enable long-term protective immunity.经鼻给药的融合抑制性脂肽可阻断小鼠体内的新冠病毒感染并产生长期保护性免疫。
Commun Biol. 2025 Jan 15;8(1):57. doi: 10.1038/s42003-025-07491-4.
2
Respiratory delivered vaccines: Current status and perspectives in rational formulation design.呼吸道给药疫苗:合理剂型设计的现状与展望
Acta Pharm Sin B. 2024 Dec;14(12):5132-5160. doi: 10.1016/j.apsb.2024.08.026. Epub 2024 Nov 4.
3
Biopolymeric Inhalable Dry Powders for Pulmonary Drug Delivery.

本文引用的文献

1
Influence of polyethylene glycol density and surface lipid on pharmacokinetics and biodistribution of lipid-calcium-phosphate nanoparticles.聚乙二醇密度和表面脂质对脂质-钙-磷纳米颗粒的药代动力学和生物分布的影响。
Biomaterials. 2014 Mar;35(9):3027-34. doi: 10.1016/j.biomaterials.2013.12.022. Epub 2014 Jan 2.
2
Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems.脂质体和脂质纳米颗粒药物递送系统的新兴研究与临床开发趋势
J Pharm Sci. 2014 Jan;103(1):29-52. doi: 10.1002/jps.23773. Epub 2013 Nov 25.
3
Discussion about several potential drawbacks of PEGylated therapeutic proteins.
用于肺部药物递送的生物聚合物可吸入干粉
Pharmaceuticals (Basel). 2024 Dec 4;17(12):1628. doi: 10.3390/ph17121628.
4
Inhaled Nanoparticulate Systems: Composition, Manufacture and Aerosol Delivery.吸入式纳米颗粒系统:组成、制造和气溶胶传递。
J Aerosol Med Pulm Drug Deliv. 2024 Aug;37(4):202-218. doi: 10.1089/jamp.2024.29117.mk.
5
Engineered lipid liquid crystalline nanoparticles as an inhaled nanoplatform for mucus penetration enhancement.工程化脂质液晶纳米颗粒作为吸入型纳米平台用于增强黏液穿透。
Drug Deliv Transl Res. 2023 Nov;13(11):2834-2846. doi: 10.1007/s13346-023-01351-6. Epub 2023 May 8.
6
Therapeutic applications of curcumin nanomedicine formulations in cystic fibrosis.姜黄素纳米药物制剂在囊性纤维化中的治疗应用。
Prog Biomater. 2022 Dec;11(4):321-329. doi: 10.1007/s40204-022-00198-3. Epub 2022 Jul 29.
7
Design, Development, Physicochemical Characterization, and In Vitro Drug Release of Formoterol PEGylated PLGA Polymeric Nanoparticles.福莫特罗聚乙二醇化聚乳酸-羟基乙酸共聚物纳米粒的设计、开发、理化性质表征及体外药物释放
Pharmaceutics. 2022 Mar 14;14(3):638. doi: 10.3390/pharmaceutics14030638.
8
A Multifunctional Neutralizing Antibody-Conjugated Nanoparticle Inhibits and Inactivates SARS-CoV-2.一种多功能中和抗体偶联纳米颗粒抑制和失活 SARS-CoV-2。
Adv Sci (Weinh). 2022 Jan;9(2):e2103240. doi: 10.1002/advs.202103240. Epub 2021 Nov 10.
9
Formoterol PLGA-PEG Nanoparticles Induce Mitochondrial Biogenesis in Renal Proximal Tubules.福莫特罗 PLGA-PEG 纳米粒诱导肾小管近端粒体生物发生。
AAPS J. 2021 Jun 24;23(4):88. doi: 10.1208/s12248-021-00619-4.
10
Design and Comprehensive Characterization of Tetramethylpyrazine (TMP) for Targeted Lung Delivery as Inhalation Aerosols in Pulmonary Hypertension (PH): In Vitro Human Lung Cell Culture and In Vivo Efficacy.用于肺动脉高压(PH)吸入气雾剂靶向肺部递送的川芎嗪(TMP)的设计与综合表征:体外人肺细胞培养和体内疗效
Antioxidants (Basel). 2021 Mar 11;10(3):427. doi: 10.3390/antiox10030427.
讨论聚乙二醇化治疗性蛋白的几个潜在缺点。
Biol Pharm Bull. 2014;37(3):335-9. doi: 10.1248/bpb.b13-00661. Epub 2013 Dec 12.
4
Systemic delivery of biotherapeutics through the lung: opportunities and challenges for improved lung absorption.生物治疗药物通过肺部的全身递送:改善肺部吸收的机遇与挑战
Ther Deliv. 2013 Dec;4(12):1511-25. doi: 10.4155/tde.13.119.
5
Surface engineering of liposomes for stealth behavior.脂质体的表面工程实现隐形行为。
Pharmaceutics. 2013 Oct 25;5(4):542-69. doi: 10.3390/pharmaceutics5040542.
6
How can we bring high drug doses to the lung?我们如何将高剂量药物递送到肺部?
Eur J Pharm Biopharm. 2014 Jan;86(1):1-6. doi: 10.1016/j.ejpb.2013.11.005. Epub 2013 Dec 1.
7
Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer's disease.用于脑部给药治疗阿尔茨海默病的碱性成纤维细胞生长因子鼻内纳米颗粒。
Int J Pharm. 2014 Jan 30;461(1-2):192-202. doi: 10.1016/j.ijpharm.2013.11.049. Epub 2013 Dec 1.
8
PEGylated nanomedicines: recent progress and remaining concerns.聚乙二醇化纳米药物:最新进展与尚存问题。
Expert Opin Drug Deliv. 2014 Jan;11(1):139-54. doi: 10.1517/17425247.2014.866651. Epub 2013 Dec 3.
9
Alternative carriers in dry powder inhaler formulations.干粉吸入剂配方中的替代载体。
Drug Discov Today. 2014 May;19(5):618-26. doi: 10.1016/j.drudis.2013.11.013. Epub 2013 Nov 21.
10
Encapsulation into PEG-liposomes does not improve the bioavailability of pulmonary delivered salmon calcitonin.包封于 PEG-脂质体中并不会提高肺递送鲑鱼降钙素的生物利用度。
J Aerosol Med Pulm Drug Deliv. 2014 Feb;27(1):1-11. doi: 10.1089/jamp.2013.1049. Epub 2013 Nov 19.